ESG

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

A new documentary focusing on resilience after 9/11 is gaining global acclaim, merging powerful filmmaking with a mission to educate future generations.

A new venture plans to transform Los Angeles's legacy oil fields into clean power plants for the AI industry, bypassing an already strained energy grid.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

Silfab Solar appoints financial veteran Phung Ngo-Burns as CFO, a strategic move to navigate its major U.S. expansion amid a booming domestic solar market.

Valant's AI Notes Assist now supports 100+ templates, aiming to reduce clinician burnout by fitting into existing workflows, not forcing new ones.

A new partnership brings AI voice analysis to home caregiving, promising proactive support for seniors but raising new questions about privacy in our living rooms.

Vishay's VOx619A series sets a new standard for industrial electronics with unmatched energy efficiency, signal integrity, and high-temperature performance.

At MWC 2026, IP Infusion launched OcNOS 7.0, targeting AI data centers and 400G/800G optical transport with an open, cost-saving platform.

Oat Foundry launches Chroma Flap, a vibrant kinetic wall that uses mechanical motion and sound to transform interiors into living, multi-sensory art.

IMO Health integrates a global rare disease database into EHRs, promising to shorten diagnosis times and accelerate vital research for millions.

As Nicholas Bell heads to the Royal Ontario Museum, Melanie Kjorlien will steer Glenbow's landmark reopening and its pioneering free admission model.

A new economic study finds West Virginia's greyhound racing industry doesn't pay for itself, surviving on millions in subsidies with no net benefit to the state.

Mahzi Therapeutics has dosed its first patient in a landmark study, offering a potential breakthrough for a rare and severe neurogenetic disorder.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

A new exclusive deal pairs NeutronX's AI and federal access with NextNRG's energy tech, aiming to overhaul critical U.S. infrastructure and national security.

With record growth and new security tools, Addigy is redefining Apple device management, challenging rivals and setting a new standard for IT teams.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Amid a volatile market, Rock Tech Lithium's latest funding from existing investors signals strong confidence in its strategy to build a local battery supply chain.